Patents by Inventor Samuel Weiss

Samuel Weiss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150339154
    Abstract: Implementing static loaders and savers for the transfer of local and distributed data containers to and from storage systems can be difficult because there are so many different configurations of output formats, data containers and storage systems. Described herein is an extensible componentized data transfer framework for performant and scalable authoring of data loaders and data savers. Abstracted local and distributed workflows drive selection of plug-ins that can be composed by the framework into particular local or distributed scenario loaders and savers. Reusability and code sparsity are maximized.
    Type: Application
    Filed: May 23, 2014
    Publication date: November 26, 2015
    Applicant: Microsoft Corporation
    Inventors: Tong Wen, Parry Husbands, Samuel Weiss
  • Publication number: 20150158894
    Abstract: The present invention relates to novel compounds, compositions containing same and methods for inhibiting STAT3 and/or STAT5 activity or for the treatment of a STAT3 or STAT5-dependent cancer using said compounds; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
    Type: Application
    Filed: May 24, 2013
    Publication date: June 11, 2015
    Inventors: Patrick Thomas Gunning, Sina Haftchenary, Brent David George Page, Samuel Weiss, Hema Artee Luchman, Melissa L. Fishel
  • Publication number: 20150163572
    Abstract: A speaker or microphone module includes an acoustic membrane and at least one pressure vent. The pressure vent equalizes barometric pressure on a first side of the acoustic membrane with barometric pressure on a second side of the acoustic membrane. Further, the pressure vent is located in an acoustic path of the speaker or microphone module. In this way, differences between barometric pressures on the different sides of the acoustic membrane may not hinder movement of the acoustic membrane. In one or more implementations, the pressure vent may be acoustically opaque. As the pressure vent is located in the acoustic path of the speaker or microphone module, being acoustically opaque may ensure that the pressure vent itself does not interfere with the operation of the speaker or microphone module.
    Type: Application
    Filed: December 5, 2013
    Publication date: June 11, 2015
    Applicant: Apple Inc.
    Inventors: Samuel Weiss, David M. Pelletier, Jesse A. Lippert, Nikolas T. Vitt
  • Publication number: 20150085429
    Abstract: A ceramic material having an electronic component embedded therein, and more particularly to a sapphire surface having an electrically energized component embedded within. In some embodiments, the sapphire surface may take the form of a portion of a housing for an electronic device. Since sapphire may be substantially transparent, it may form a cover glass for a display within or forming part of the electronic device, as one example. The cover glass may be bonded, affixed, or otherwise attached to a remainder of the housing, thereby forming an enclosure for the electronic device.
    Type: Application
    Filed: September 23, 2013
    Publication date: March 26, 2015
    Applicant: Apple Inc.
    Inventors: Dale N. Memering, Erik G. de Jong, Fletcher R. Rothkopf, Samuel Weiss
  • Patent number: 8470777
    Abstract: The present invention relates to a method to increase oligodendrocytes and oligodendrocyte precursor cells through administration of prolactin or a prolactin inducing agent.
    Type: Grant
    Filed: May 6, 2011
    Date of Patent: June 25, 2013
    Assignee: Stem Cell Therapeutics Corp.
    Inventors: Christopher Gregg, Samuel Weiss
  • Patent number: 8435949
    Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using a pheromone, a luteinizing hormone (LH) and/or a human chorionic gonadotrophin (hCG). The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from or suspected of having neurodegenerative diseases or conditions.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: May 7, 2013
    Assignee: Stem Cell Therapeutics Corp.
    Inventors: Samuel Weiss, Emeka Enwere, Linda Andersen, Christopher Gregg
  • Publication number: 20120329714
    Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using prolactin. The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from neurodegenerative diseases or conditions. In addition, since neural stem cells are a source for olfactory neurons, the present invention also provides methods of increasing olfactory neurons and enhancing olfactory functions.
    Type: Application
    Filed: June 28, 2012
    Publication date: December 27, 2012
    Applicant: STEM CELL THERAPEUTICS INC.
    Inventors: Tetsuro Shingo, Samuel Weiss
  • Patent number: 8333974
    Abstract: The present invention provides effective dosing regimes for neural stem cell proliferating agents, kits containing effective dosing regimes for neural stem cell proliferating agents, and uses thereof. In particular, neural stem cell proliferating agents, such as hCG, prolactin and EPO are delivered to mammalian subjects at low doses in a continuous fashion over several days, as opposed to delivery of high doses in a short period of time.
    Type: Grant
    Filed: March 16, 2007
    Date of Patent: December 18, 2012
    Assignee: Stem Cell Therapeutics Corp.
    Inventors: Samuel Weiss, Christopher Gregg, Allen Davidoff, Joseph Tucker
  • Publication number: 20120270779
    Abstract: Effective dosing regimens for neural stem cell proliferating and differentiating agents, kits comprising effective dosing regimens for neural stem cell proliferating and differentiating agents, and uses thereof are provided herein. Such kits and methods can be utilized acutely or chronically to treat a neurodegenerative disease or condition. Furthermore, the compositions and methods can be used continuously or intermittently in various dosing regimens.
    Type: Application
    Filed: February 21, 2012
    Publication date: October 25, 2012
    Applicant: STEM CELL THERAPEUTICS CORP.
    Inventors: Samuel Weiss, Christopher Gregg, Allen Davidoff, Joseph E. Tucker
  • Publication number: 20120244111
    Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using a pheromone, a luteinizing hormone (LH) and/or a human chorionic gonadotrophin (hCG). The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from or suspected of having neurodegenerative diseases or conditions.
    Type: Application
    Filed: June 11, 2012
    Publication date: September 27, 2012
    Applicant: Stem Cell Therapeutics Corp.
    Inventors: Samuel WEISS, Emeka ENWERE, Linda ANDERSEN, Christopher GREGG
  • Publication number: 20120189575
    Abstract: This invention relates to methods of producing oligodendrocytes from multipotent neural stem cells by using at least one oligodendrocyte promoting factor, particularly granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, interleukin 3 or interleukin 5. The neural stem cells may optionally be expanded prior to being subjected to the oligodendrocyte promoting factor.
    Type: Application
    Filed: March 19, 2012
    Publication date: July 26, 2012
    Applicant: Stem Cell Therapeutics Inc.
    Inventor: Samuel Weiss
  • Patent number: 8222212
    Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using prolactin. The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from neurodegenerative diseases or conditions. In addition, since neural stem cells are a source for olfactory neurons, the present invention also provides methods of increasing olfactory neurons and enhancing olfactory functions.
    Type: Grant
    Filed: December 29, 2010
    Date of Patent: July 17, 2012
    Assignee: Stem Cell Therapeutics Inc.
    Inventors: Tetsuro Shingo, Samuel Weiss
  • Patent number: 8217002
    Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using a pheromone, a luteinizing hormone (LH) and/or a human chorionic gonadotrophin (hCG). The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from or suspected of having neurodegenerative diseases or conditions.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: July 10, 2012
    Assignee: Stem Cell Therapeutics Corp.
    Inventors: Samuel Weiss, Emeka Enwere, Linda Andersen, Christopher Gregg
  • Patent number: 8143220
    Abstract: Effective dosing regimens for neural stem cell proliferating and differentiating agents, kits comprising effective dosing regimens for neural stem cell proliferating and differentiating agents, and uses thereof are provided herein. Such kits and methods can be utilized acutely or chronically to treat a neurodegenerative disease or condition. Furthermore, the compositions and methods can be used continuously or intermittently in various dosing regimens.
    Type: Grant
    Filed: March 16, 2007
    Date of Patent: March 27, 2012
    Assignee: Stem Cell Therapeutics Corp.
    Inventors: Samuel Weiss, Christopher Gregg
  • Publication number: 20120064028
    Abstract: The present invention relates to a method to increase oligodendrocytes and oligodendrocyte precursor cells through administration of prolactin or a prolactin inducing agent.
    Type: Application
    Filed: May 6, 2011
    Publication date: March 15, 2012
    Applicant: STEM CELL THERAPEUTICS CORP.
    Inventors: Christopher Gregg, Samuel Weiss
  • Publication number: 20110269681
    Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using prolactin. The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from neurodegenerative diseases or conditions. In addition, since neural stem cells are a source for olfactory neurons, the present invention also provides methods of increasing olfactory neurons and enhancing olfactory functions.
    Type: Application
    Filed: December 29, 2010
    Publication date: November 3, 2011
    Applicant: STEM CELL THERAPEUTICS INC.
    Inventors: Tetsuro Shingo, Samuel Weiss
  • Publication number: 20110182853
    Abstract: The present invention is related to the discovery of a novel class of neural progenitor cells, which proliferate in response to platelet derived growth factor (PDGF) and differentiate into neurons and oligodendrocytes but not astrocytes. Progeny of the progenitor cells can be obtained by culturing brain tissue in PDGF without serum, epidermal growth factor (EGF), fibroblast growth factor 2, or transforming growth factor alpha. Upon subculturing into EGF-containing media, these progeny cells can proliferate and form neurospheres, whereas PDGF has no such effect.
    Type: Application
    Filed: April 7, 2011
    Publication date: July 28, 2011
    Applicant: STEM CELL THERAPEUTICS INC.
    Inventors: Samuel Weiss, Andrew K. Chojnacki
  • Publication number: 20110178009
    Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using a pheromone, a luteinizing hormone (LH) and/or a human chorionic gonadotrophin (hCG). The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from or suspected of having neurodegenerative diseases or conditions.
    Type: Application
    Filed: October 29, 2010
    Publication date: July 21, 2011
    Applicant: STEM CELL THERAPEUTICS CORP.
    Inventors: Samuel Weiss, Emeka Enwere, Linda Andersen, Christopher Gregg
  • Patent number: 7964563
    Abstract: The present invention relates to a method to increase oligodendrocytes and oligodendrocyte precursor cells through administration of prolactin or a prolactin inducing agent.
    Type: Grant
    Filed: April 7, 2009
    Date of Patent: June 21, 2011
    Assignee: Stem Cell Therapeutics Corp.
    Inventors: Christopher Gregg, Samuel Weiss
  • Patent number: 7943376
    Abstract: The present invention is related to the discovery of a novel class of neural progenitor cells, which proliferate in response to platelet derived growth factor (PDGF) and differentiate into neurons and oligodendrocytes but not astrocytes. Progeny of the progenitor cells can be obtained by culturing brain tissue in PDGF without serum, epidermal growth factor (EGF), fibroblast growth factor 2, or transforming growth factor alpha. Upon subculturing into EGF-containing media, these progeny cells can proliferate and form neurospheres, whereas PDGF has no such effect.
    Type: Grant
    Filed: April 25, 2002
    Date of Patent: May 17, 2011
    Assignee: Stem Cell Therapuetics Inc.
    Inventors: Samuel Weiss, Andrew K. Chojnacki